News | March 12, 2014

On-X Life Technologies to launch its On-X Plus 1.5 Aortic Heart Valve at Society for Cardiothoracic Surgery

March 12, 2014 — Privately held On-X Life Technologies Inc. (On-X LTI) launched its European marketing campaign for the On-X Plus 1.5 Aortic Heart Valve in concert with its Great Britain distributor Vascutek Corp. at the Annual Meeting & Cardiothoracic Forum of the Society for Cardiothoracic Surgery in Great Britain & Ireland, March 10-12, Edinburgh, Scotland.

In January, On-X LTI received European regulatory approval for an expanded labeling claim, which now permits the company to market its breakthrough mechanical heart valve in Europe with a reduced requirement for the use of anticoagulants (warfarin). The On-X Plus 1.5 aortic heart valve is the only heart valve that allows patients to be managed at INR (International Normalized Ratio) levels as low as 1.5-2.0. An INR blood test measures the time it takes for patients’ blood to clot.

“Europe has been waiting for just such guidance from a leading mechanical valve producer, and we are very happy to see On-X take this lead with the new labeling on its product,” said John McKenna, vice president of cardiothoracic business development for Vascutek Ltd., a subsidiary of Terumo Corp. “Cardiac surgeons in the UK immediately presented us with an order on hearing of or catching sight of the new labeling. We are very excited by the prospects for patients, surgeons and hospitals.”

“We are extremely pleased with the market’s eagerness to embrace our state-of-the-art On-X Plus 1.5 valve,” addedClyde Baker, president and CEO of On-X LTI. “In Europe the On-X aortic valve is unique among all other mechanical valves and also offers a new option to patients in their 50s and 60s who are considering a tissue valve. These patients are expected to live an additional 20 years. Tissue valve failure is documented to occur between eight to 16 years post-implant. Replacement valve surgery will be necessary for these patients when they are in their 70’s and 80’s. Now that it has been shown to be safe to use the On-X mechanical valve with low levels of warfarin, these patients and their surgeons have a new valve option available, and the early response of clinicians has been very encouraging.”

The European expanded labeling claim was supported by interim data from a recently completed arm of an FDA IDE clinical trial — Prospective Randomized On-X Anticoagulation Clinical Trial (“PROACT”) — presented by principal investigator John D. Puskas, M.D., Cardiothoracic Surgery, Emory University, Atlanta, at the annual scientific meeting of the American Association for Thoracic Surgery (AATS) in 2013. These data demonstrated the safety of maintaining On-X aortic heart valve patients on a reduced anticoagulation therapy regimen while decreasing bleeding complications by 60 percent.

For more information: www.onxlti.com

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Overlay Init